Morgan Stanley’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-7,649
| Closed | -$66K | – | 6965 |
|
|
2018
Q2 | $66K | Sell |
7,649
-49,925
| -87% | -$449K | ﹤0.01% | 5848 |
|
|
2018
Q1 | $584K | Buy |
57,574
+4,616
| +9% | +$38.8K | ﹤0.01% | 4911 |
|
|
2017
Q4 | $256K | Sell |
52,958
-198
| -0.4% | -$963 | ﹤0.01% | 5323 |
|
|
2017
Q3 | $242K | Sell |
53,156
-23,945
| -31% | -$112K | ﹤0.01% | 5255 |
|
|
2017
Q2 | $390K | Buy |
77,101
+1,524
| +2% | +$6.82K | ﹤0.01% | 4961 |
|
|
2017
Q1 | $359K | Buy |
75,577
+17,774
| +31% | +$89.8K | ﹤0.01% | 5030 |
|
|
2016
Q4 | $324K | Sell |
57,803
-6,674
| -10% | -$36.6K | ﹤0.01% | 5151 |
|
|
2016
Q3 | $358K | Sell |
64,477
-1,090
| -2% | -$7.21K | ﹤0.01% | 4725 |
|
|
2016
Q2 | $459K | Sell |
65,567
-28,790
| -31% | -$203K | ﹤0.01% | 4479 |
|
|
2016
Q1 | $623K | Sell |
94,357
-117,056
| -55% | -$861K | ﹤0.01% | 4283 |
|
|
2015
Q4 | $2.18M | Sell |
211,413
-115,776
| -35% | -$1.34M | ﹤0.01% | 3417 |
|
|
2015
Q3 | $3.85M | Buy |
327,189
+250,958
| +329% | +$2.77M | ﹤0.01% | 2887 |
|
|
2015
Q2 | $698K | Sell |
76,231
-6,074
| -7% | -$45.9K | ﹤0.01% | 4472 |
|
|
2015
Q1 | $511K | Sell |
82,305
-5,987
| -7% | -$37K | ﹤0.01% | 4640 |
|
|
2014
Q4 | $494K | Sell |
88,292
-1,800
| -2% | -$10.5K | ﹤0.01% | 4671 |
|
|
2014
Q3 | $530K | Sell |
90,092
-2,214
| -2% | -$13.5K | ﹤0.01% | 4529 |
|
|
2014
Q2 | $633K | Sell |
92,306
-36
| -0% | -$241 | ﹤0.01% | 4411 |
|
|
2014
Q1 | $666K | Buy |
92,342
+2,507
| +3% | +$17.3K | ﹤0.01% | 4346 |
|
|
2013
Q4 | $594K | Buy |
89,835
+33,676
| +60% | +$229K | ﹤0.01% | 4319 |
|
|
2013
Q3 | $408K | Buy |
+56,159
| New | +$378K | ﹤0.01% | 4468 |
|
Morgan Stanley's JNP Position: Q3 2018 in Review
Morgan Stanley sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 7,649 shares — an estimated $66K sold.
Morgan Stanley first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $3.85M in Q3 2015. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Morgan Stanley reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Morgan Stanley sold 7,649 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $66K.
- Morgan Stanley first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 20 quarters.
- Morgan Stanley's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $3.85M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Morgan Stanley's 13F filing for Q3 2018, filed 14 Nov 2018.